Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2009 February;100(1) > Minerva Medica 2009 February;100(1):69-78



A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669


Minerva Medica 2009 February;100(1):69-78



The cost-effectiveness of treatment of age-related macular degeneration: a review

Kymes Steven M. 1,3

1 Department of Ophthalmology and Visual Sciences Washington University School of Medicine, St. Louis, MO, USA
2 Division of Biostatistics, Washington University School of Medicine St. Louis, MO, USA
3 Center for Health Policy, Washington University School of Medicine St. Louis, MO, USA

Age-related macular degeneration (AMD) is a disease of the retina, most often seen among people over the age of 50. The disease is typically manifested by the loss of central vision and as such represents a major threat to the quality of life to those suffering with it. This report reviewed the evidence concerning the economic impact of macular degeneration in the developed world, examining reports on direct and indirect medical costs, as well as those that have attempted to estimate non-health care costs. It also aimed to review reports of the cost-effectiveness of treatment of the disease, examining nutritional supplements, photodynamic therapy, and anti-VEGF treatments.

language: English


top of page